Ocular Drug Delivery System Challenges and New Advancements

Suhail K

doi:10.61280/tjpls.v13i2.233

Suhail K Shri Jagdishprasad Jhabarmal Tibrewala University (JJTU) Vidyanagari, Jhunjhunu-Churu Road, Chudela, District Jhunjhunu, Rajasthan - 333010

DOI: https://doi.org/10.61280/tjpls.v13i2.233

Keywords:

Ocular drug delivery, Ocular barriers, Bioavailability, Controlled drug release, Nanoparticles, Liposomes, In-situ gelling systems, Intracameral Drug delivery, Punctal plug drug delivery system

Abstract

Ocular medication delivery remains one of the most difficult areas of pharmaceutical science due to the eye's unique anatomical and physiological obstacles. Drug absorption and bioavailability are considerably limited by protective mechanisms including as tear turnover, blinking, nasolacrimal drainage, corneal epithelial tight junctions, and the blood-aqueous and blood-retinal barriers.

Conventional dose formulations, such as eye drops and ointments mostly have a short residence time and low therapeutic efficacy, demanding frequent administration and resulting to lower patient compliance. Furthermore, posterior segment disorders such as age-related macular degeneration, diabetic retinopathy, and glaucoma necessitate focused and continuous drug delivery techniques that overcome both static and dynamic ocular obstacles.

Recent advancements in ocular drug delivery systems have focused on improving bioavailability, prolonging precorneal retention, enabling controlled release, and enhancing tissue targeting. Innovative approaches include nanoparticle-based systems (polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers), liposomes, niosomes, dendrimers, micelles, and in situ gelling systems. Biodegradable and non-biodegradable implants, microneedles, ocular inserts, and contact lens mediated delivery have also demonstrated promising outcomes for sustained and site-specific therapy. Furthermore, emerging technologies such as stimuli-responsive systems, gene delivery vectors, and nanofiber-based platforms are expanding therapeutic possibilities for both anterior and posterior segment disorders.

Downloads

Download data is not yet available.

Author Biography

Suhail K, Shri Jagdishprasad Jhabarmal Tibrewala University (JJTU) Vidyanagari, Jhunjhunu-Churu Road, Chudela, District Jhunjhunu, Rajasthan - 333010

Research Scholar

References

Khurana, AK and Khurana, B (2012), Textbook of Comprehensive Ophthalmology, New Age International Publisher, 5th ed., New Delhi, 89-94.

Tripathi, KD (2010), Essentials of Medical Pharmacology, Jaypee Publishers, 6th ed., New Delhi, 688-693.

Mitra, AK (2003), Ophthalmic Drug Delivery Systems, Library of Congress Cataloging-in-Publication, 2nd ed., USA, 309-320.

Melton, R and Thomas, R (2016), Clinical Guide to Ophthalmic Drugs, Review of Optometry, Vol. 20, 3-10.

Patel, PB; Shastri, DH; Shelat, PK and Shukla, AK (2010), “Ophthalmic drug delivery system: Challenges and approaches”, Syst Rev Pharm, Vol. 1 (2), 113-119.

Tortora, GJ and Nicholas, P (1987), Textbook of Principles of Human Anatomy, 5th ed., 500-520.

Bachu, RD; Chowdhury, P; Al-Saedi, ZH et al. (2018), “Ocular Drug Delivery Barriers—Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases”, Pharmaceutics, Vol. 10 (1), 28.

Ali, M and Byrne, ME (2008), “Challenges and Solutions in Topical Ocular Drug-Delivery Systems”, Expert Rev Clin Pharmacol, Vol. 1 (1), 145-161.

Ahmed, S; Amin, MM and Sayed, S (2023), “Ocular Drug Delivery: A Comprehensive Review”, AAPS PharmSciTech, Vol. 24, 66.

Barar, J; Javadzadeh, AR and Omidi, Y (2008), “Ocular Novel Drug Delivery: Impacts of Membranes and Barriers”, Expert Opin Drug Deliv, Vol. 5 (5), 567-581.

Lin, X; Zhou, Y; Lv, K et al. (2025), “Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases”, Int J Nanomedicine, Vol. 20, 9221-9249.

Bairagi, R; Rahman, R; Hasan, MM et al. (2025), “Ocular Drug Delivery Systems Based on Nanotechnology: A Comprehensive Review”, J Nanobiotechnol, Vol. 20, 75.

Khaledian, S; Abdoli, M; Mirzaee, S and Nokhodchi, A (2025), “Nanostructure Colloids in Ocular Drug Delivery: Advances and Challenges”, Chem Pap, Vol. 79, 7299-7322.

Yang, Y and Lockwood, A (2022), “Topical ocular drug delivery systems: Innovations for an unmet need”, Exp Eye Res, Vol. 218, 109006.

Ali, M., & Byrne, M. E. (2008). Challenges and solutions in topical ocular drug-delivery systems. Expert Review of Clinical Pharmacology, 1(1), 145-161.

Ali, M. & Byrne, M. E. (2008) Challenges and solutions in topical ocular drug-delivery systems. Expert Review of Clinical Pharmacology;1(1):145-161.

Barar, J; Javadzadeh, AR and Omidi, Y (2008), “Ocular novel drug delivery: Impacts of membranes and barriers”, Expert Opin Drug Deliv, Vol. 5 (5), 567-581.

Jumelle, C; Gholizadeh, S; Annabi, N and Dana, R (2020), “Advances and limitations of drug delivery systems formulated as eye drops”, J Control Release, Vol. 321, 1-22.

Wang, Y and Wang, C (2022), “Novel eye drop delivery systems: Advance on formulation design strategies targeting anterior and posterior segments of the eye”, Pharmaceutics, Vol. 14 (6), 1150.

Bachu, RD; Chowdhury, P; Al-Saedi, ZH; Karla, PK; Boddu, SHS and Tutunji, L (2018), “Ocular drug delivery barriers—Role of nanocarriers in the treatment of anterior segment ocular diseases”, Pharmaceutics, Vol. 10 (1), 28.

Jumelle, C; Gholizadeh, S; Annabi, N and Dana, R (2020), “Advances and limitations of drug delivery systems formulated as eye drops”, J Control Release, Vol. 321, 1-22.

Wang, R; Gao, Y; Liu, A and Zhai, G (2021), “A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: Challenges, analysis and recent advances”, J Drug Target, Vol. 29 (7), 687-702.

Li, J; Liu, H; Zhang, X and Xu, Y (2017), “Nanoparticle-based drug delivery systems for ocular disease: Current status and future perspectives”, Asian J Pharm Sci, Vol. 12 (3), 212-223.

Yadav, KS and Rajpurohit, R (2019), “Nanotechnology-based ocular drug delivery systems: Recent advances and future prospects”, J Drug Deliv Sci Technol, Vol. 52, 278-290.

Stapleton, F; Keay, L; Edwards, K; Naduvilath, T; Dart, JKG; Brian, G and Holden, BA (2008), “The incidence of contact lens–related microbial keratitis in Australia”, Ophthalmology, Vol. 115 (10), 1655-1662.

Ciolino, JB; Hoare, TR; Iwata, NG; Behlau, I; Dohlman, CH; Langer, R and Kohane, DS (2009), “A drug-eluting contact lens”, Invest Ophthalmol Vis Sci, Vol. 50 (7), 3346-3352.

Montan, PG; Wejde, G; Setterquist, H; Rylander, M and Zetterström, C (2002), “Prophylactic intracameral cefuroxime: Evaluation of safety and kinetics in cataract surgery”, J Cataract Refract Surg, Vol. 28 (6), 982-987.

Shorstein, NH; Winthrop, KL and Herrinton, LJ (2013), “Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a large integrated health care system”, Ophthalmology, Vol. 120 (1), 1-4.

Chang, DF; Braga-Mele, R; Henderson, BA; Mamalis, N; Vasavada, A and ASCRS Cataract Clinical Committee (2014), “Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery: Results of the 2014 ASCRS survey”, J Cataract Refract Surg, Vol. 40 (9), 1460-1468.

Behndig, A; Cochener, B; Guell, JL; Kodjikian, L; Mencucci, R; Nuijts, RMMA and Pleyer U (2013), “Endophthalmitis prophylaxis in cataract surgery: Overview of current practice patterns in Europe”, J Cataract Refract Surg, Vol. 39 (11), 1809-1816.

Gupta, C and Chauhan, A (2011), “Ophthalmic delivery of cyclosporine A by punctal plugs”, J Control Release, Vol. 150 (1), 70–76.

Yellepeddi, VK; Sheshala, R; McMillan, H and others (2015), “Punctal plug: a medical device to treat dry eye syndrome and for sustained drug delivery to the eye”, Drug Discov Today, Vol. 20 (7), 884–889.

Xu, X; Awwad, S; Diaz-Gomez, L and others (2021), “3D Printed Punctal Plugs for Controlled Ocular Drug Delivery”, Pharmaceutics, Vol. 13 (9), 1421.

Gautam, M; Gupta, R; Singh, P; Verma, V; Verma, S; Mittal, P; Karkhur, S; Sampath, A; Mohan, RR and Sharma, B (2023), “Intracameral drug delivery: a review of agents, indications, and outcomes”, J Ocul Pharmacol Ther, Vol. 39 (2), 102–116.

Kiernan, DF (2020), “Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery”, BMJ Open Ophthalmol, Vol. 5 (1), e000491.

Hosny, MH; Zayed, MA; Shalaby, AM and Eissa, IM (2009), “Effect of intracameral bevacizumab injection on corneal endothelial cells: an in vivo evaluation”, J Ocul Pharmacol Ther, Vol. 25 (6), 513–517.

Pimenta, AFR; Serro, AP; Colaço, R and Chauhan, A (2018), “Drug delivery to the eye anterior chamber by intraocular lenses: an in vivo concentration estimation model”, Eur J Pharm Biopharm, Vol. 133, 63–69.

Ari, S; Nergiz, Y; Aksit, I; Sahin, A; Cingu, K and Caca, I (2015), “Evaluation of intracameral injection of ranibizumab and bevacizumab on the corneal endothelium by scanning electron microscopy”, J Ocul Pharmacol Ther, Vol. 31 (2), 100–105.